Niva Bupa Health Insurance sees distribution reform support margins and growth

Investment View and Regulatory Outlook

In its September 24, 2026 company update on Niva Bupa Health Insurance, Motilal Oswal Financial Services retained its Buy rating and one-year target price of Rs 100, while maintaining its estimates.

The broker views the IRDAI consultation paper on distribution regulations as a medium-term positive for the health insurance industry and Niva Bupa. However, insurers may need to reassess product structures and distribution architecture in the near term, which could weigh on growth.

Management described the proposed distribution changes as net positive. Retail health accounted for about 75 per cent of the Q1 book and is expected to benefit as lower commissions allow Niva Bupa to hold premiums flat for longer. Management expects higher volumes to offset lower distributor commission rates.

Distribution Channel Implications

Retail Agency Business

The proposed agency caps of 20 per cent in the first year and 10 per cent on renewal are close to Niva Bupa's existing payouts. Management believes agents can preserve absolute income through higher ticket sizes, renewals, ageing, upselling and cross-selling. It does not expect the retail business to be adversely affected in the short to medium term.

Banca, Digital and Group Business

Management remains positive on banca growth and economics despite a sharper commission reduction. It plans to reinvest in bank accounts rather than accept lower absolute payouts, arguing that the revised rates remain profitable for banks because of their near-zero variable cost. As a precedent, management said monthly retail business from banks doubled within 12 months after the loss of GST input-tax credit.

Digital broker economics are also viewed positively, although final commission rates remain uncertain. Group and B2B business, which accounts for about 8 per cent of the book, is seen as neutral to marginally positive, with the pricing cycle expected to remain the larger driver.

Credit-Linked Business and Key Mitigants

The principal adverse impact is expected in credit-linked business, which accounted for about 15 per cent of FY26 gross written premium. Management expects volumes to decline, although the scale of the effect has not yet been quantified.

Potential mitigants include adding lender relationships, increasing penetration at existing lenders and a signed memorandum of understanding with a life insurer for a combined term life, credit life and health offering. Management considers the business low combined-ratio but one-time in nature, with limited lifetime customer value, and expects the lost contribution to be more than offset elsewhere.

Operating Leverage and Profitability Targets

Management expects the expense-over-management ratio to decline from about 34–35 per cent of gross written premium to 25 per cent within two years and about 20 per cent within five years. The improvement is expected to come from operating leverage in manpower and fixed costs as premiums scale, rather than from cost cutting.

Management retained its target of a 98–99 per cent combined ratio by FY29 and 15–18 per cent return on equity, with a formal review after Q2 FY27. It expects commission savings to be passed to customers through deferred or smaller premium increases. This should raise loss ratios by roughly the commission saved while keeping the combined ratio near target.

Direct-to-consumer business remains about 10 percentage points less costly than intermediated business, supporting continued investment in that channel.

Financial Performance and Estimates

The report shows the following FY26 financial figures and FY27E–FY28E forecasts:

Motilal Oswal's forecasts imply gross earned premium growth at a 25 per cent compound annual rate over FY26–FY29E. The combined ratio is expected to improve from 101.5 per cent in FY26 to 99.6 per cent in FY28E, while return on equity is forecast to expand from 10.6 per cent to 14.4 per cent.

Valuation Disclosure

The report provides forecast P/E and price-to-book multiples but does not specify a separate valuation methodology for the retained Rs 100 target price.